Agoracom Blog

Applied BioSciences $APPB Subsidiary, Trace Analytics, Receives Extension of Contract of Services from Washington State Department of Agriculture $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:37 AM on Wednesday, December 18th, 2019
  • Trace Analytics Inc. is a leading scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing
  • WSDA contracted Trace Analytics for the purpose of doing cannabinoid profiling for the State’s industrial hemp program to ensure the percentages of certain cannabinoids are below Federal limits

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced that the Washington State Department of Agriculture (WSDA) has extended its contract for services with Applied’s majority owned subsidiary, Trace Analytics Inc. (“Trace”).

The WSDA contracted Trace beginning in July 2019 for the testing of Industrial Hemp samples and percentage testing for delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

“We are grateful for our relationship with the WSDA and are pleased to continue cannabinoid profiling for the WSDA’s Industrial Hemp program. The testing and reporting of results that we have conducted to date have demonstrated the quality of our analytics and our dedication to ensuring compliance with Federal limits,” stated Jason Zitzer, Chief Operating Officer of Trace Analytics. “We provide expert consulting services to government entities at all levels around the world and are appreciative to WSDA to have been selected as the sole lab to conduct their testing. This contract extension provides another opportunity toward establishing a higher quality for cannabis and hemp testing.”

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology, focused on ensuring compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally with the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing. The Company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

Based on Applied BioSciences’ stated strategic corporate shift to focus on its BioPharma division and the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS), the Company is currently evaluating a strategic transaction of Trace Analytics. Applied is currently in late-stage discussions and expects to close the transaction by year end.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Can Better Internet Connectivity in India Give Education a Push? – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca #Edtech

Posted by AGORACOM-JC at 5:57 PM on Tuesday, December 17th, 2019
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Can Better Internet Connectivity in India Give Education a Push?

  • Leveraging internet connectivity, edtech apps are personalising practice sessions for millions of children
  • Using advanced technology like artificial intelligence and machine learning, edtech apps study individual student behaviour

By: Zisshan Hayath

Let’s go back to the time when Facebook first made its entrance in India. Most people didn’t have computers at home – and they would end up travelling a few kilometres just to reach a cyber cafe and access social networks. Instant messages and emails received slower replies and even owning a mobile phone was a luxury for the youth. Cheap mobile data was unheard of.

In just a little over a decade, the scene in India is completely different. Every other person, especially in urban areas, has access to mobile phones and laptops. India has one of the cheapest mobile data plans in the world. This has revolutionised the way mobile phones are used, even perceived.

Today, mobile devices have gone beyond their primary role of interpersonal connectivity. Today, mobile devices are a mode of convenience, entertainment, consumerism and education.

Initially, the term e-learning was only used in the context of large scale MNCs helping their employees learn on the go by eliminating classrooms. In the span of a few years, of the 300 million school going students, several million have registered themselves on e-learning apps.

So how is internet connectivity helping Indian students learn better for better results?

Accessibility:

In a traditional learning setup, quality teachers, books, and infrastructure are only concentrated in metros and education hubs. With the internet becoming easily affordable, eLearning apps leverage this connectivity to ensure that every child in in the country has access to high-quality teachers. Using live classes, children can watch India’s best teachers explain complex concepts, ask questions, and get them answered in real-time.

Personalisation:

The teacher-student ratio in Indian classrooms is extremely skewed, with one teacher for about 30-35 students on average. This number gets worse in tier II and III cities. Due to this, teachers cannot give students any personal attention. They use a one-size-fits-all approach for every child, without considering their aptitude, grasping power, strengths, and weaknesses. Due to India’s vast population and weak infrastructure, it is a mammoth task to improve this.

However, this can be easily resolved using edtech. Leveraging internet connectivity, edtech apps are personalising practice sessions for millions of children. Using advanced technology like artificial intelligence and machine learning, edtech apps study individual student behaviour.

Using this data, they start every student’s practice at a level that they’re comfortable with. The difficulty of questions is then increased until the student meets their individual learning goals.

24×7 Instant Doubt Resolution:

One of the key hindrances in every student’s learning journey is doubts. In a classroom set up, students end up waiting for weeks, if not months until the teacher completes the syllabus and then organises doubt-solving sessions. The end result is that the student’s learning journey is affected and so is their understanding of not just the topic in question, but other topics as well. They end up rote learning these topics, but this does not help when they appear for national level board or competitive exams.

Using internet connectivity, learning apps have created a chat platform where students can ask their questions. They are instantly connected to an expert who resolves their doubt for them in under a minute.

In fact, this platform, often called Live Doubts or Doubts on Chat has become so popular, that edtech apps are using natural language processing to create a bot that can answer student doubts instantly, based on the millions of questions asked earlier. If the bot cannot find an answer, or if the student has any further questions, the student can choose to chat with a live expert. As of now, over 25 percent of all doubts are solved using this bot.

Internet is bringing a revolution in every industry across India. From booking a cab to movie tickets, groceries, and games – every industry has undergone a major shift for the better. It’s now time for parents to embrace edtech and help their children learn better.

(Zishaan Hayath is the Founder and CEO of Toppr, a learning app that provides personalised learning for students studying for boards, Olympiads, and various engineering and medical competitive exams.) Chennai: In little over 3 months since video platform Tiktok ..

Read more at:
http://timesofindia.indiatimes.com/articleshow/72553189.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Applied BioSciences $APPB: What Is the Endocannabinoid System And What Is Its Role? $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:06 PM on Tuesday, December 17th, 2019

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info

Some of us consume cannabis for its mind-altering effects, while others seek symptom relief. But cannabis wouldn’t get us high or have some of its therapeutic benefits if our bodies didn’t already contain a biological system capable of interacting with its active chemical compounds, like THC.

Our endocannabinoid system does just that. But it isn’t there just to allow us to enjoy the effects of our favorite strain. It serves a vital purpose for our health and well-being because it regulates key aspects of our biology. So, what’s it doing, and how does it work?

Homeostasis: Staying in the Goldilocks zone

rocks on a beach

To understand the human endocannabinoid system, it’s helpful to know a little about one of the most fundamental concepts in biology: homeostasis. And the best way to understand homeostasis is to think of Goldilocks and the three bears.

That classic fairy tale illustrated the idea that the best outcome often lies somewhere in the middle, between two extremes. We don’t want things too hot or too cold, but just right.

Homeostasis is the concept that most biological systems are actively regulated to maintain conditions within a narrow range. Our body doesn’t want its temperature to be too hot or too cold, blood sugar levels too high or too low, and so on. Conditions need to be just right for our cells to maintain optimum performance, and exquisite mechanisms have evolved to draw them back to the Goldilocks zone if they move out. The body’s endocannabinoid system (ECS) is a vital molecular system for helping maintain homeostasis—it helps cells stay in their Goldilocks zone.

Key pieces of the endocannabinoid system (ECS)

Because of its crucial role in homeostasis, the ECS is widespread throughout the animal kingdom. Its key pieces evolved a long time ago, and the ECS can be found in all vertebrate species.

The three key components of the ECS are:

  • Cannabinoid receptors found on the surface of cells
  • Endocannabinoids, small molecules that activate cannabinoid receptors
  • Metabolic enzymes that break down endocannabinoids after they are used

Cannabinoid receptors

Cannabinoid receptors sit on the surface of cells and “listen” to conditions outside the cell. They transmit information about changing conditions to the inside of the cell, kick-starting the appropriate cellular response.

There are two major cannabinoid receptors: CB1 and CB2. These aren’t the only cannabinoid receptors, but they were the first ones discovered and remain the best-studied. CB1 receptors are one of the most abundant receptor types in the brain. These are the receptors that interact with THC to get people high. CB2 receptors are more abundant outside of the nervous system, in places like the immune system. However, both receptors can be found throughout the body (Figure 1).

endocannabinoid system cannabinoid receptors CB1 and CB2 in the body

Figure 1: Where are CB1 and CB2 receptors located in the body?
The CB1 and CB2 receptors are key players in the endocannabinoid system (ECS). They are located on the surface of many different types of cells in the body. Both receptors are found throughout the body, but CB1 receptors are more abundant in the central nervous system, including on neurons in the brain. In contrast, CB2 receptors are more abundant outside of the nervous system, including cells of the immune system.

Endocannabinoids

Endocannabinoids are molecules that, like the plant cannabinoid THC, bind to and activate cannabinoid receptors. However, unlike THC, endocannabinoids are produced naturally by cells in the human body (“endo” means “within,” as in within the body).

There are two major endocannabinoids: anandamide and 2-AG (Figure 2). These endocannabinoids are made from fat-like molecules within cell membranes, and are synthesized on-demand. This means that they get made and used exactly when they’re needed, rather than packaged and stored for later use like many other biological molecules.

Anandamide and 2-AG are the two major endocannabinoids produced naturally in the body

Figure 2: Anandamide and 2-AG are the two major endocannabinoids.
Cannabinoids are a class of molecules characterized by their ability to activate cannabinoid receptors like CB1 and CB2. Anandamide and 2-AG are the two major endocannabinoids produced naturally in the body. THC is the psychoactive plant cannabinoid produced by Cannabis. All three of these cannabinoids can activate the CB1 and CB2 receptors, although each one has a different potency at each receptor.

Metabolic enzymes

The third piece of the endocannabinoid triad includes the metabolic enzymes that quickly destroy endocannabinoids once they are used. The two big enzymes are FAAH, which breaks down anandamide, and MAGL, which breaks down 2-AG (Figure 3). These enzymes ensure that endocannabinoids get used when they’re needed, but not for longer than necessary. This distinguishes endocannabinoids from many other molecular signals in the body, such as hormones or classical neurotransmitters, which can persist for many seconds or minutes, or get packaged and stored for later use.

FAAH and MAGL are the key enzymes of the endocannabinoid system

Figure 3: FAAH and MAGL are the key enzymes of the endocannabinoid system.
Enzymes are molecules that accelerate chemical reactions in the body, often for breaking down molecules. FAAH and MAGL are key players in the ECS because they quickly break down endocannabinoids. FAAH breaks down anandamide, while MAGL breaks down 2-AG. These enzymes break down endocannabinoids very quickly, but are not effective at breaking down plant cannabinoids like THC.

The three key components of the ECS can be found within almost every major system of the body. When something brings a cell out of its Goldilocks zone, these three pillars of the ECS are often called upon to bring things back, thus maintaining homeostasis. Because of its role in helping bring things back to their physiological Goldilocks zone, the ECS is often engaged only when and where it’s needed. Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry in Italy, put it to us this way:

“With the ‘pro-homeostatic action of the ECS’ we mean that this system of chemical signals gets temporarily activated following deviations from cellular homeostasis. When such deviations are non-physiological, the temporarily activated ECS attempts, in a space- and time-selective manner, to restore the previous physiological situation (homeostasis).”

In other words, the ECS helps bring things back to the biological Goldilocks zone.

Below we will consider examples of how the ECS helps maintain homeostasis in two areas: the firing of brain cells in the nervous system, and the inflammatory response of the immune system.

Endocannabinoid regulation of brain cell firing

Brain cells (neurons) communicate by sending electrochemical signals to each another. Each neuron must listen to its partners to decide whether it will fire off its own signal at any given moment. However, neurons don’t like to get too much input—there’s a Goldilocks zone. If they get overloaded by signals, it can be toxic. That’s where endocannabinoids come in.RelatedHow Does Cannabis Consumption Affect the Brain?

Consider a simplified scenario with one neuron listening to two others. One of these two neurons might become overactive and send too many signals to the neuron that’s listening. When that happens, the neuron that’s listening will make endocannabinoids specifically where it’s connected to the overactive neuron. Those endocannabinoids will travel back to the “loud” neuron where they bind to CB1 receptors, transmitting a signal that instructs it to quiet down. This brings things back to the Goldilocks zone, maintaining homeostasis (Figure 4).

endocannabinoid system regulation of brain cell firing

Figure 3: Endocannabinoid signals regulate how active our brain cells are.
Under normal circumstances (top-left), a given brain cell (neuron) will get just the right amount of input from its partners—not too much, not too little. However, some of its partners can become overactive, and send an excessive number of signals (top-right). The neuron that’s listening will detect this, and release endocannabinoids that tell the other neuron to quiet down (bottom). This kind of mechanism helps maintain homeostasis because it helps prevent neurons from sending out too many signals.

As the example above illustrates, endocannabinoids travel backwards, which is why they’re known as retrograde signals. Most of the time, information flow between neurons is strictly in one direction, from “sender” neurons that release neurotransmitter signals to “receiver” neurons that listen to those signals. Endocannabinoids allow receiver neurons to regulate how much input they’re getting, and they do this by sending retrograde signals (endocannabinoids) back to overactive sender neurons.

But the brain isn’t the only organ that needs to maintain homeostasis. Every other system of the body, from the digestive to the immune system, needs to carefully regulate how its cells are functioning. Proper regulation is crucial for ensuring survival.

Endocannabinoid regulation of inflammation

Inflammation is a natural protective reaction the immune system has in response to infection or physical damage. The purpose of inflammation is to remove pathogens (germs) or damaged tissue. The inflamed area is produced by fluid and immune cells moving into the area to do the dirty work and return things to their Goldilocks zone.

It’s important that inflammation be limited to the location of damage and doesn’t persist longer than needed, which can cause harm. Chronic inflammation and auto-immune diseases are examples of the immune system getting activated inappropriately. When that happens, the inflammatory response lasts too long (which results in chronic inflammation) or gets directed toward healthy cells (which is known as auto-immunity).RelatedCannabis and Arthritis

In general, endocannabinoids seem to suppress or limit the immune system’s inflammatory signals. Professor Prakash Nagarkatti, Vice President for Research at the University of South Carolina whose laboratory studies endocannabinoid regulation of immune responses, told us how tweaking the ECS might be a good way to treat inflammatory diseases.

“Most of our research demonstrates that endocannabinoids are produced upon activation of immune cells and may help regulate the immune response by acting as anti-inflammatory agents. Thus, interventions that manipulate the metabolism or production of endocannabinoids may serve as a novel treatment modality against a wide range of inflammatory disease.”

Consider a normal immune response triggered by a bacterial infection. First, immune cells detect the presence of bacteria and release pro-inflammatory molecules that tell other immune cells to come and join the fight. Endocannabinoids get released as well (Figure 4), which also signal to other immune cells for assistance and likely help limit the inflammatory response so it isn’t excessive. By tightly regulating inflammation, the immune system can destroy germs or remove damaged tissue, and then stop. This prevents excessive inflammation, allowing cells, and thus the body, to return to the Goldilocks zone.

the endocannabinoid system and inflammation

Figure 4: Endocannabinoids help regulate inflammation.
Under normal conditions (top-left), cells of the immune system patrol the body, on alert for any intruders, such as bacteria. During a bacterial infection (top-right), immune cells detect the presence of bacteria and then release a variety of molecules to help mount a defensive attack (bottom). These signals include pro-inflammatory molecules (small circles) that help recruit more immune cells to the site of infection. Endocannabinoids (small diamonds) also get released, and likely help regulate the magnitude and extent of this inflammatory response.

How do plant cannabinoids like THC and CBD interact with the endocannabinoid system?

The reason that plant cannabinoids have psychoactive and medicinal effects within the body is, in large part, because we have an endocannabinoid system (ECS) that they can interact with. For example, THC gets you high because it activates the CB1 receptor within the brain. Endocannabinoids like anandamide also activate CB1.

So why aren’t we constantly high?

A couple big reasons. First, THC doesn’t interact with CB1 receptors in exactly the same fashion as the body’s natural endocannabinoids. Second, the metabolic enzymes that quickly break down endocannabinoids like anandamide don’t work on THC, so THC lingers around for much longer.

It’s important to remember that molecules like cannabinoids and other neurotransmitters rarely interact with only one receptor type; they often interact with many. The plant-based cannabinoid CBD illustrates this nicely, as it interacts with numerous receptor types in the brain. So, while plant cannabinoids may activate the same cannabinoid receptors as endocannabinoids, they will likely interact with several other receptors and therefore have distinct effects.

CBD is also interesting because it can affect overall levels of endocannabinoids in the brain, referred to as “endocannabinoid tone.” CBD inhibits the FAAH enzyme, which breaks down anandamide. Thus, CBD can increase anandamide levels by preventing FAAH from breaking it down. Inhibiting the FAAH enzyme has been shown to be a useful strategy for treating anxiety disorders, and some of CBD’s anti-anxiety properties may come from its ability to inhibit this enzyme and thereby increase endocannabinoid tone.

Summary

The endocannabinoid system (ECS), comprised of cannabinoid receptors, endocannabinoid molecules, and their metabolic enzymes, is a crucial molecular system that the body uses to help maintain homeostasis. Because of its vital role in making sure that cells and systems remain in their physiological Goldilocks zone, the ECS is tightly regulated; it gets deployed exactly when and where it’s needed. However, this doesn’t mean that activating the ECS, through consumption of cannabis or by any other means, will always make things just right.

Like any other complex biological system, the ECS can go awry. “If deviation from physiological homeostasis is prolonged, due to either external factors or chronic pathological conditions, the eCS can lose its time- and space-selective mode of action and start affecting inappropriate cells,” Dr. Di Marzo explained. “In these cases, the ECS, instead of being beneficial, may actually contribute to disease progression.”

It’s important to remember that activating the ECS, through cannabis consumption or by any other means, isn’t a cure-all. Like most of biology, it’s complicated.

By understanding the biological Goldilocks principle (homeostasis), and how the ECS illustrates this at the cellular level, we can more deeply appreciate why we have an ECS to begin with, and how a variety of cannabis-based therapies might actually work. The presence and critical function of the ECS across many systems of the body, including the nervous and immune systems, explains why such a wide variety of ailments and disease states are responsive to cannabis-based interventions.


References
Gunduz-cinar O, Hill MN, Mcewen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34(11):637-44. [PDF]
Ligresti A, De petrocellis L, Di marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev. 2016;96(4):1593-659. [PDF]
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-49. [PDF]
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [PDF]
Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82. [PDF]
Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17. [PDF]

ThreeD Capital Inc. $IDK.ca – Will 2020 Be The Year Of Enterprise #Bitcoin? #Ethereum $HIVE.ca $BLOC.ca $CODE.ca

Posted by AGORACOM-JC at 3:58 PM on Tuesday, December 17th, 2019

SPONSOR: ThreeD Capital Inc. (IDK:CSE) Led by legendary financier, Sheldon Inwentash, ThreeD is a Canadian-based venture capital firm that only invests in best of breed small-cap companies which are both defensible and mass scalable. More than just lip service, Inwentash has financed many of Canada’s biggest small-cap exits. Click Here For More Information.

Will 2020 Be The Year Of Enterprise Bitcoin?

  • Bitcoin is the most popular digital asset in the institutional trading world as it has the best trading options available, both spot and derivatives, proven track record with the longest history and availability of data.
  • This made some of the largest financial services institutions highly interested and in 2019 we saw the birth of several bitcoin products like Bakkt’s physically delivered bitcoin futures, Fidelity Digital Assets bitcoin custody solution and TD Ameritrade’s trading offerings.

Biser Dimitrov

It also the case for the large enterprises looking at blockchain as technology and wanting to innovate using easier payments over fast and secure transaction networks and processes built around smart contracts? Can they use the bitcoin blockchain as a foundation and place their middleware stack and end-user decentralized Web 3 and decentralized finance (DeFi) applications on top?

So far the majority of enterprise-focused blockchain development has been done on permissioned and private blockchain protocols like Hyperledger Fabric and R3’s Corda. This is mostly due to the fact that they offer sufficient privacy, scalability and transaction finality guarantees. Compared to them, development on top of the bitcoin blockchain was not seriously considered until recently when in May, Microsoft announced their permissionless, Decentralized Identifier (DID) network called ION running exclusively on top of the bitcoin blockchain. That triggered a shift in the sentiment that developers and enterprises should also consider bitcoin as a potential layer for enterprise blockchain development. For example, companies like Bitfury are already making significant progress with enterprise-tailored blockchain offerings like blockchain as a service (BaaS) using bitcoin as a base layer.

Let’s review how bitcoin stacks up as an enterprise-ready development platform. According to a recent Ernst & Young study among decision makers across the U.S., Europe and Asia, the major reasons to consider blockchain in general are:

· Preservation of data integrity – In this area bitcoin is the absolute winner as the most trusted and secure public blockchain. The bitcoin blockchain is currently secured by 97 quintillion hashes per second, or EH/s. Data integrity is priority number one for the maintainers of the bitcoin blockchain and they are very restrictive about any new feature that can introduce security bugs and potentially compromise the integrity of the protocol. The accuracy and consistency of the data can be easily observed and analyzed by simple blockchain explorers as well as by using surveillance tools like Elliptic, Elementus and Chainalysis.

· Ability to build new revenue/business models – Bitcoin currently has a $128 billion liquid market cap so building new models on top of it can unlock new significant revenue channels. Furthermore, the increased adoption of Layer 2 technology like the Lightning Network, which operate via channels and enable cheap and fast payments, will enable new business processes and ways to revenue.

· Increased operational efficiency – Since 2010, when certain opcodes were taken out of the core protocol, smart contracts were considered taboo in bitcoin. Lately, with the development of Blockstream’s Liquid and the new RSK framework, Schnorr signatures and Taproot will make smart contracts–like executions possible via sidechains.

Source: https://www.forbes.com/sites/biserdimitrov/2019/12/17/will-2020-be-the-year-of-enterprise-bitcoin/#402c169e3647

Deficit-hit #palladium takes aim at $2,000 ceiling in record run – SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 2:53 PM on Tuesday, December 17th, 2019

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

Deficit-hit palladium takes aim at $2,000 ceiling in record run

  • “Supply is tight in the palladium market and when you’re adding the speculation about a potential pick-up in demand due to recovery in the global economy, you have a perfect storm of bullish news continuing to keep it supported,” Saxo Bank analyst Ole Hansen said.

(Reuters) – Scarce palladium soared on Tuesday, nearing a breach of the $2,000 an ounce level for the first time, with a “phase one” U.S.-China trade deal driving prospects of a pick-up in demand and helping the autocatalyst metal extend a record run.

Palladium was up 0.6% at $1,989.58 an ounce at 1035 GMT, after hitting an all-time high of $1,998.43.

“Supply is tight in the palladium market and when you’re adding the speculation about a potential pick-up in demand due to recovery in the global economy, you have a perfect storm of bullish news continuing to keep it supported,” Saxo Bank analyst Ole Hansen said.

However, he added: “Liquidity is poor, which means that if we see a correction, it can be quite brutal and could take palladium back down towards $1,850, although there are no signs of that right now.”

The phase one trade deal has been “absolutely completed”, a top White House adviser said on Monday. However, Chinese officials have been more cautious, emphasizing the dispute has not been completely settled.

Palladium, used mainly in vehicle catalytic converters, has gained more than 57% so far this year because of a sustained supply crunch.

“We look set for an imminent test above $2,000,” MKS PAMP said in a note.

Elsewhere, gold prices rose due to uncertainty driven by a lack of concrete details about the interim trade deal.

Spot gold rose 0.2% to $1,478.41 per ounce. U.S. gold futures were also up 0.2%, at $1,482.90.

The trade dispute will be an influencing factor for gold throughout next year, said Commerzbank analyst Daniel Briesemann, adding a phase two deal would be much more difficult since a lot of critical issues had been left out of the current agreement.

“We must be prepared for some volatility and uncertainty. It’s not yet a done deal.”

Gold, considered a safe investment during political and economic uncertainty, has gained about 15% this year, mainly driven by the 17-month-long tariff war and its impact on the global economy.

Also helping bullion, European stocks slid from record highs on reports that Britain’s prime minister was ready to play rough in Brexit talks, souring sentiment somewhat after a record rally during the Asian session on the trade optimism.

Silver was 0.2% higher at $17.07 per ounce, while platinum gained 0.3% to $932.32.

Source: https://www.onenewspage.us/n/Business/1zkl56ztmy/Deficit-hit-palladium-takes-aim-at-000.htm

CardioComm Solutions $EKG.ca – #Mhealth Technologies Market Projected to Gain Significant Value $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:59 AM on Tuesday, December 17th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Mobile Health (MHealth) Technologies Market Projected to Gain Significant Value

By: trendsmarketresearch

  • The global mHealth market should reach $46.2 billion by 2021 from $13.2 billion in 2016 at a compound annual growth rate (CAGR) of 28.6%, from 2016 to 2021.

Report Scope:

This new report on mobile health will provide a brief description of the current status of the industry and recent developments. It presents the changing environment, in terms of new challenges and opportunities for app development, remote monitoring and networking medical data. The report analyzes the market trends, leading service providers, therapeutic markets and the most popular mHealth applications, in terms of downloads and revenues.

Report Includes:

– A global overview of the mobile health technology market.
– Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
– A presentation of the changing mobile health technology environment in terms of new challenges and rising opportunities.
– Information regarding market trends, leading service providers, therapy markets, and the most popular mHealth applications.
– Insight into the second generation of mHealth devices, projected regulatory patterns, and innovative devices and services to be launched in the near future.
– Company profiles of major players in the industries covered.

Report Summary

Mobile health (mHealth) is the use of mobile and wireless technologies to support healthcare systems and achieve healthcare objectives. Digital health solutions have the potential to improve the quality of healthcare, to democratize medical knowledge and provide healthcare to billions or people who have limited or no access to services. The provision of healthcare remains high on the economic and political agenda and continues to demand a huge share of gross domestic product (GDP) in industrialized countries, where an aging population and increase in the prevalence of chronic noncommunicable diseases (NCDs) remains a challenge.

mHealth can provide better and more consistence solutions within the global healthcare environment and will change the way services are provided in the future. Smart devices and wearable are empowering individuals to more effectively manage their care, raising awareness, providing continuous monitoring and disseminating of information to the patient and healthcare professionals; driving a more proactive, patient-centric healthcare system.

Source: https://statsflash.com/mobile-health-mhealth-technologies-market-projected-to-gain-significant-value-by-to-2021/743242/

PRIMO Nutraceuticals Inc. $PRMO.ca – Here’s Why Dollar General $DG Has High Hopes for #CBD $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 10:27 AM on Tuesday, December 17th, 2019

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

Here’s Why Dollar General Has High Hopes for CBD

By: Rich Duprey

  • Dollar General (NYSE: DG) is jumping on the CBD bandwagon, announcing it intends to start selling products infused with cannabidiol in 1,100 stores across seven states by spring 2020
  • Limiting its selection of goods to topical products such as creams, ointments, bath bombs, bath salts, and face masks. Edibles are not part of the plan.

Yet where grocery stores, shoe stores, pharmacies, and wellness stores have all previously said they, too, were joining the conga line of retailers selling CBD products, the dollar store chain’s entry has a greater chance of boosting its bottom line.

Image source: Getty Images.

Business is growing like a weed

Unlike many other retailers and even rival Dollar Tree, Dollar General is on fire, giving a master class in discount retailing in the third quarter. Sales rose 9% to $7 billion on a near-5% increase in comparable-store sales, generating a 13% rise in earnings per share. Management also raised top- and bottom line guidance for the year.

It was tough to pick out a category that was best, as it saw across-the-board sales increases, but it was enough for the discount chain to know it needed to pick up the pace of expansion. Where it expects to open 975 new stores this year, it plans on opening another 1,000 in 2020. In all, Dollar General will be involved in 20% more real estate projects next year than it was this year. 

That’s important because as it continues to reach further into all regions of the country, getting closer to its target customer, CBD products afford it the opportunity to accelerate that growth.

The madness of cannabis

Marijuana, cannabis, and cannabidiol all live in a legal purgatory. Although a number of states have legalized marijuana for personal use, it officially remains a controlled dangerous substance at the federal level.

Cannabis, on the other hand, essentially comprises two categories, marijuana and hemp, with the major difference being the presence of tetrahydrocannabinol, or THC, the psychoactive compound that gets a user high. While hemp does contain THC, it is at very low levels and not enough to get someone high. The 2018 Farm Bill removed hemp and hemp-derived products from its list of controlled dangerous substances.

CBD is one of over 100 compounds found in cannabis, but unlike THC, it doesn’t get you high. Also, where marijuana has very little CBD, hemp has a lot. Many also believe CBD has a variety of therapeutic properties, and though some studies have seemingly backed up the claim, there haven’t been very many studies, and the long-term implications from its use are still unknown. 

A green business 

The Food and Drug Administration is slow-walking the formulation of a coherent policy on CBD, which has put many retailers in limbo on just how best to proceed. What the FDA was clear about in its recent policy update, however, was that it is illegal to add CBD to food or supplements. That’s why you see retailers opting for topical applications of the compound. 

Cannabidiol has another benefit for the retail industry in that it enjoys over dried cannabis, or so-called legal weed. Consumers have demonstrated willingness to pay up for the compound, and there is a plentiful supply of CBD, suggesting profits will remain stable. 

That’s an attractive feature for low-margin businesses like grocery stores. But Dollar General, which sells merchandise at many different price points, tends to make up in volume what it loses out in product markups. Driving down the cost of CBD-infused products could cause consumers to flock to its stores. 

And for a discount chain, Dollar General is a relatively high-profit-margin business. Over the past five years, its operating margins stand at almost 9% and net margins are 6%. But compare that with other retailers that have announced they will be selling CBD products.

Retailer5-Year Operating Margin5-Year Net Margin
Dollar General8.9%6%
Dollar Tree8.4%2.5%
CVS Health 5.6%2.6%
Rite Aid 1.6%2.1%
Walgreens 4.6%3.5%
Kroger 2.6%1.9%

Data source: Morningstar. 

A smoking hot opportunity

The retail market is expected to be the biggest contributor to CBD’s growth, accounting for 60% of the forecast $20 billion in annual sales. Dollar General has the potential to bring CBD products to more people and attract a bigger share of the market because of its value proposition.

While there may be questions about the viability and efficacy of the CBD in the products it offers (a question that looms over all retailers selling CBD products), CBD has a higher chance of moving the needle for Dollar General than it does for anyone else. Source: https://www.nasdaq.com/articles/heres-why-dollar-general-has-high-hopes-for-cbd-2019-12-17

NORTHBUD $NBUD.ca – Ontario sold the most #cannabis in first year of legalization $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:20 PM on Monday, December 16th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Ontario sold the most cannabis in first year of legalization

  • Ontario accounted for $217 million in recreational cannabis sales — or 24 per cent of the overall Canadian market
  • From October 2018 to September 2019, followed by Alberta and Quebec, which sold $196 million and $195 million worth, respectively

By: Vanmala Subramaniam

Cannabis retailers in Ontario sold the most cannabis of any province in the first year following legalization, even though there was only one online store and 24 brick-and-mortar stores in operation for most of that period, according to new Statistics Canada data.

Ontario accounted for $217 million in recreational cannabis sales — or 24 per cent of the overall Canadian market — from October 2018 to September 2019, followed by Alberta and Quebec, which sold $196 million and $195 million worth, respectively.

The year following legalization saw more than 400 brick-and-mortar stores established across the country. Total adult-use cannabis sales from online retail stores amounted to $908 million for that period, far short of many estimates prior to legalization.

For instance, a June 2018 report from CIBC estimated that legal cannabis sales could reach $6.5 billion by 2020, with the potential to yield $1 billion in EBITDA. A similar report by Deloitte had forecast the legal cannabis market to generate $4.3 billion in sales in the year following legalization.

The StatsCanada data also observed a sharp decline in the number of consumers who purchased cannabis online, in tandem with the growth of the number of retail stores across the country. The share of online sales declined from 43.4 per cent in Oct. 2018 to just 5.9 per cent the following September, while the number of brick-and-mortar stores rose 88 per cent between March and July 2019.

Online retail stores — most of which are operated by provincial wholesalers — made approximately $120 million in the year following legalization, while brick-and-mortar stores raked in the remaining $788 million in sales.

Indeed, government-run stores have been struggling. Ontario Cannabis Retail Corp. which operates the Ontario Cannabis Store, lost $42 million in its latest fiscal year ending March 31, 2019. In New Brunswick, Cannabis NB, the crown corporation in charge of selling cannabis, recently said it was looking for a buyer, as losses piled up.

On a per capita basis, British Columbia reported the lowest sales values in the country at $10 per capita in the year following legalization. Ontario did not fare much better on that measure, with a per capita sales value of $15. Alberta, by contrast, had one of the highest per capita sales values at $45.

Statistics Canada attributed these vast differences to varying access to cannabis stores. In Ontario, for instance, just nine per cent of residents lived within a three kilometre distance to a cannabis store, whereas in Alberta — the province with the highest number of stores — 50 per cent of residents lived within three kilometres of a cannabis store.

The Canadian cannabis industry has, for the most part, struggled to meet expectations from both investors and consumers, with price, quality and accessibility being the key reasons why the sector did not take off at a rate many had hoped it would.

While the first few months of legalization were characterized by a supply shortage, the production ramp-up in the latter half of 2019 has now created the opposite problem: oversupply.

Cannabis producers are urging the Ontario government to open up the licensing process for retail stores, which they hope will lead to a sharp growth in the number of stores across Canada’s most populous province.

Source: https://business.financialpost.com/cannabis/cannabis-business/ontario-sold-the-most-cannabis-in-first-year-of-legalization-despite-low-store-count

#Palladium prices rally to record high – SPONSOR: New Age Metals $NAM.ca $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 4:24 PM on Monday, December 16th, 2019

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces Inferred. Learn More.

Palladium prices rally to record high

  • “Palladium has been on a multi-year run that shows few signs of abating,” John Ciampaglia, chief executive officer of Sprott Asset Management

by Denton Staff Contributor

Palladium futures rallied Friday to their highest settlement on record, extending last year’s advance and narrowing their price spread with gold to the smallest in roughly 16 years.

“Palladium has been on a multi-year run that shows few signs of abating,” John Ciampaglia, chief executive officer of Sprott Asset Management, wrote in a recent report. “Palladium is close to becoming the most ‘precious’ of precious metals.”

Palladium, which is used in pollution-controlling catalytic converters on gasoline-powered vehicles, has been significantly narrowing its spread with gold prices.

‘Palladium is close to becoming the most “precious” of precious metals.’ John Ciampaglia, Sprott Asset Management

On Friday, March palladium  added $34.10, or 2.8%, to settle at $1,234.40 an ounce. The finish was the highest based on FactSet records dating back to November 1984, topping the previous record settlement of $1,201.30 from Dec. 19.

February gold  fell $9, or 7%, to finish at $1,285.80 an ounce dulled investment demand in the yellow metal. That helped narrow its spread with palladium futures down to $51.40, the lowest since November 2002, according to Dow Jones Market Data. The last time palladium settled higher than gold was in October 2002.

Overall, growing global demand for the industrial metal has fed worries about tighter supplies.

“While the escalating U.S.-China trade war hurt many commodities in 2018, it couldn’t dent palladium’s rise,” said Ciampaglia. “Demand for palladium was especially strong last year, as environmental concerns have prompted a global shift from diesel to gasoline and hybrid vehicles.”

“Not even the 2018 slowdown in China’s auto market, the world’s largest, dampened demand,” he said.

Auto sales in China, the biggest global market, were on track for their annual decline in three decades after plunging 16% in November.

News Friday on progress toward a U.S.-China trade deal was upbeat, however. China’s Commerce Ministry confirmed that a delegation of U.S. officials will travel to Beijing for a new round of trade talks on Monday and Tuesday, .

“Supply shortages continue to support palladium’s performance, with strong multi-year growth in palladium demand now straining a fixed supply,” Ciampaglia said. “Palladium is especially scarce and its supply is inelastic since it is usually a by-product of ores that are being mined for other metals, like platinum and rhodium.”

Source: https://dentondaily.com/palladium-prices-rally-to-record-high-now-nearing-golds-level/

CardioComm Solutions $EKG.ca – #Mhealth Market Latest Innovations and Industry Analysis $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 2:29 PM on Monday, December 16th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Digital Health Market Latest Innovations and Industry Analysis

  • Rapid Adoption of mHealth Technologies Drives the Market
  • “Rising number of government initiatives aimed at promoting digital health solutions will enable growth in the market,”

The Global Digital Health Market is driven by several factors. “Rising number of government initiatives aimed at promoting digital health solutions will enable growth in the market,” said a lead analyst at Fortune Business insights. “In the coming years the digital health market is estimated to benefit from the uptake of IT in the medical industry,” he added. With the increasing use of smartphones across the world the demand for digital health services is growing owing to the rising adoption of mhealth apps.

Other factors such as the rising demand for in-house remote monitoring devices and increasing geriatric population will catalyze growth of the digital health and wellness services. Digital health over the past few years has become a game changer in the digital health industry. Digital health services help in monitoring diseases and provide access to electronic information of patients through tablets or mobiles. Doctors can check the complete digital health record of their patients and accordingly offer the best consultation. All the factors mentioned above are anticipated to boost the digital health market during the forecast period.

Read More: http://rentfint.com/2019/12/16/digital-health-market-latest-innovations-industry-analysis-segmentation-research-report-opportunities-forecast-till-2026/